Dr. Adam Cohen discussed the role of quadruplet induction regimens for transplant-ineligible patients with multiple myeloma at the ASCO Annual Meeting. The IMROZ and BENEFIT trials showed that the combination of isatuximab with bortezomib, lenalidomide, and dexamethasone was more effective for newly diagnosed older patients than the standard treatment option. This suggests that quadruplet regimens may be a viable option for older patients with multiple myeloma. Cohen, an associate professor of medicine in hematology-oncology, highlighted the importance of considering quadruplet treatments for this patient population. The trials’ results were presented at the ASCO Annual Meeting in Chicago.
Source link
Isatuximab-VRd more effective in treating older patients with multiple myeloma
